Abstract

Pertussis is a contagious respiratory tract disease caused by the Gram-negative bacterium Bordetella pertussis. Despite widespread vaccination, in recent years the pertussis incidence has increased. The whole-cell pertussis vaccine has been very effective but reactogenic. Therefore the improved vaccines contain only a few isolated and inactivated antigens of B. pertussis. However, a waning of the acellular vaccine-induced immunity indicates that these vaccines lack some important protective B. pertussis antigens. The vaccine containing an inactivated pertussis toxin induces the production of toxin-neutralizing antibodies, but it does not lead to destruction of bacteria. Since many virulence factors are involved in the pathogenesis of pertussis, beside the toxin-neutralizing activity, the direct bactericidal activity is essential in anti-pertussis immunity. Lipooligosaccharide is the main surface component of B. pertussis. It is a target for bactericidal antibodies during natural infection. The endotoxic activity of LOS makes it unacceptable for acellular vaccines against B. pertussis. However, the non-toxic moiety of the B. pertussis LOS-derived oligosaccharide coupled to a carrier protein forms an immunogenic glycoconjugate which has a potential application as a new component of a pertussis vaccine.In this paper, we present a review of current research and reasons for the increased pertussis incidence. The epidemiologic situation of pertussis in the past decades showing the ineffectiveness of contemporary, acellular pertussis vaccines is also discussed. The immune processes elicited by natural infection with B. pertussis were compared to the vaccine-induced immunity. The important role of bactericidal antibodies against lipooligosaccharide was indicated in effective immune defense. In a number of research papers the immunogenicity and protective properties of glycoconjugates containing the oligosaccharide component of B. pertussis have been described, and its application as a new component of a pertussis vaccine have been implied.

References

• 1. Albitar-Nehme S., Basheer S.M., Njamkepo E., Brisson J.R., GuisoN., Caroff M.: Comparison of lipopolysaccharide structures of Bordetellapertussis clinical isolates from pre- and post-vaccine era. Carbohydr.Res., 2013; 378: 56-62
  Google Scholar
• 2. Archambault D., Rondeau P., Martin D., Brodeur B.R.: Characterizationand comparative bactericidal activity of monoclonal antibodiesto Bordetella pertussis lipo-oligosaccharide A. J. Gen. Microbiol.,1991; 137: 905-911
  Google Scholar
• 3. Avery O.T., Goebel W.F.: Chemo-immunological studies on conjugatedcarbohydrate-proteins: II. Immunological specificity of syntheticsugar-protein antigens. J. Exp. Med., 1929; 50: 533-550
  Google Scholar
• 4. Bechini A., Tiscione E., Boccalini S., Levi M., Bonanni P.: Acellularpertussis vaccine use in risk groups (adolescents, pregnant women,newborns and health care workers): a review of evidences and recommendations.Vaccine, 2012; 30: 5179-5190
  Google Scholar
• 5. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., BassaniD.G., Jha P., Campbell H., Walker C.F., Cibulskis R., Eisele T., Liu L.,Mathers C., Child Health Epidemiology Reference Group of WHO andUNICEF: Global, regional, and national causes of child mortality in2008: a systematic analysis. Lancet, 2010; 375: 1969-1987
  Google Scholar
• 6. Burns D.L., Kenimer J.G., Manclark C.R.: Role of the A subunit ofpertussis toxin in alteration of Chinese hamster ovary cell morphology.Infect. Immun., 1987; 55: 24-28
  Google Scholar
• 7. Caroff M., Brisson J., Martin A., Karibian D.: Structure of the Bordetellapertussis 1414 endotoxin. FEBS Lett., 2000; 477: 8-14
  Google Scholar
• 8. Caroff M., Karibian D.: Structure of bacterial lipopolysaccharides.Carbohydr. Res., 2003; 338: 2431-2447
  Google Scholar
• 9. Centers for Disease Control and Prevention: Pertussis Chapter- Epidemiology of Vaccine-Preventable Diseases. The Pink Book:Course Textbook. 2015
  Google Scholar
• 10. Centers for Disease Control and Prevention (CDC): Pertussisvaccination: use of acellular pertussis vaccines among infants andyoung children. Recommendations of the Advisory Committee onImmunization Practices (ACIP). MMWR Recomm. Rep., 1997; 46: 1-25
  Google Scholar
• 11. Centers for Disease Control and Prevention (CDC): Pertussisepidemic – Washington, 2012. MMWR Morb. Mortal. Wkly. Rep.,2012; 61: 517-522
  Google Scholar
• 12. Chaby R., Caroff M.: Lipopolysaccharides of Bordetella pertussisendotoxin. W: Pathogenesis and immunity in pertussis. John-Wiley& Sons, Chichester, United Kingdom 1988, 247-271
  Google Scholar
• 13. Cherry J.D.: Epidemic pertussis in 2012 — the resurgence ofa vaccine-preventable disease. N. Engl. J. Med., 2012; 367: 785-787
  Google Scholar
• 14. Cherry J.D.: Why do pertussis vaccines fail? Pediatrics, 2012;129: 968-970
  Google Scholar
• 15. Chodorowska M., Kuklińska D.: Krztusiec u młodzieży i osóbdorosłych. Przegl. Epidemiol., 2001; 55: 189-195
  Google Scholar
• 16. Chodorowska M., Kuklińska D.: Restrykcyjna analiza DNA pa-łeczek Bordetella pertussis wyizolowanych od chorych na krztusiecw 1968 roku i w latach 1995-98 oraz szczepów B. pertussis stosowanychdo produkcji krajowej szczepionki przeciwkrztuścowej. Med.Dośw. Mikrobiol., 2001; 52: 111-117
  Google Scholar
• 17. Clark T.A.: Changing pertussis epidemiology: everything old isnew again. J. Infect. Dis., 2014; 209: 978-981
  Google Scholar
• 18. Dagan R., Poolman J., Siegrist C.A.: Glycoconjugate vaccinesand immune interference: a review. Vaccine, 2010; 28: 5513-5523
  Google Scholar
• 19. De Gouw D., Diavatopoulos D.A., Bootsma H.J., Hermans P.W.,Mooi F.R.: Pertussis: a matter of immune modulation. FEMS Microbiol.Rev., 2011; 35: 441-474
  Google Scholar
• 20. Edwards K.M., Berbers G.A.: Immune responses to pertussis vaccinesand disease. J. Infect. Dis., 2014; 209 (Suppl. 1): S10-S15
  Google Scholar
• 21. Elomaa A., He Q., Minh N.N., Mertsola J.: Pertussis before andafter the introduction of acellular pertussis vaccines in Finland.Vaccine, 2009; 27: 5443-5449
  Google Scholar
• 22. Farizo K.M., Burns D.L., Finn T.M., Gruber M.F., Pratt R.D.: Clinicalevaluation of pertussis vaccines: US Food and Drug Administrationregulatory considerations. J. Infect. Dis., 2014; 209 (Suppl. 1): S28-S31
  Google Scholar
• 23. Finco O., Rappuoli R.: Designing vaccines for the twenty-firstcentury society. Front. Immunol., 2014; 5: 12
  Google Scholar
• 24. Flak T.A., Goldman W.E.: Signalling and cellular specificity ofairway nitric oxide production in pertussis. Cell. Microbiol., 1999;1: 51-60
  Google Scholar
• 25. Guiso N.: Bordetella pertussis and pertussis vaccines. Clin. Infect.Dis., 2009; 49: 1565-1569
  Google Scholar
• 26. Guiso N.: Bordetella pertussis: why is it still circulating? J. Infect.,2014; 68 (Suppl. 1): S119-S124
  Google Scholar
• 27. Gzyl A., Augustynowicz E., Gniadek G., Ślusarczyk J.: Zmiennośćgenetyczna szczepów Bordetella pertussis. Część II. Perspektywy naprzyszłość. Przegl. Epidemiol., 2003; 57: 193-200
  Google Scholar
• 28. Gzyl A., Augustynowicz E., Rabczenko D., Gniadek G., SlusarczykJ.: Pertussis in Poland. Int. J. Epidemiol., 2004; 33: 358-365
  Google Scholar
• 29. Gzyl A., Augustynowicz E., Zawadka M., Rabczenko D., SlusarczykJ.: Ocena efektywności pełnokomórkowych i bezkomórkowychszczepionek przeciw krztuścowi w eliminacji eksperymentalnegozakażenia myszy Bordetella pertussis. Med. Dośw. Mikrobiol., 2007;59: 123-135
  Google Scholar
• 30. Heidary N., Cohen D.: Hypersensitivity reactions to vaccinecomponents. Dermatitis, 2005; 16: 115-120
  Google Scholar
• 31. Heininger U.: Recent progress in clinical and basic pertussisresearch. Eur. J. Pediatr., 2001; 160: 203-213
  Google Scholar
• 32. Hermanson G.T.: The reactions of bioconjugation. W: Techniques(Third Edition). Academic Press, 2013, 229-258
  Google Scholar
• 33. Higgins S.C., Jarnicki A.G., Lavelle E.C., Mills K.H.: TLR4 mediatesvaccine-induced protective cellular immunity to Bordetella pertussis:role of IL-17-producing T cells. J. Immunol., 2006; 177: 7980-7989
  Google Scholar
• 34. Higgs R., Higgins S.C., Ross P.J., Mills K.H.: Immunity to the respiratorypathogen Bordetella pertussis. Mucosal Immunol., 2012; 5:485-500
  Google Scholar
• 35. Jennings H.J., Ługowski C.: Immunochemistry of groups A, B,and C meningococcal polysaccharide-tetanus toxoid conjugates. J.Immunol., 1981; 127: 1011-1018
  Google Scholar
• 36. Jennings H.J., Ługowski C., Ashton F.E.: Conjugation of meningococcallipopolysaccharide R-type oligosaccharides to tetanus toxoidas route to a potential vaccine against group B Neisseria meningitidis.Infect. Immun., 1984; 43: 407-412
  Google Scholar
• 37. Kerr J.R., Matthews R.C.: Bordetella pertussis infection: pathogenesis,diagnosis, management, and the role of protective immunity.Eur. J. Clin. Microbiol. Infect. Dis., 2000; 19: 77-88
  Google Scholar
• 38. Kimura A., Beurret M., Cowell J.L.: Immunogenic conjugates ofnontoxic oligosaccharide derived from Bordetella pertussis lipooligosaccharide.Patent EP0471954. 1992
  Google Scholar
• 39. Klein N.P., Bartlett J., Fireman B., Rowhani-Rahbar A., Baxter R.:Comparative effectiveness of acellular versus whole-cell pertussisvaccines in teenagers. Pediatrics, 2013; 131: e1716-e1722
  Google Scholar
• 40. Klein N.P., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R.:Waning protection after fifth dose of acellular pertussis vaccine inchildren. N. Engl. J. Med., 2012; 367: 1012-1019
  Google Scholar
• 41. Koepke R., Eickhoff J.C., Ayele R.A., Petit A.B., Schauer S.L., HopfenspergerD.J., Conway J.H., Davis J.P.: Estimating the effectivenessof tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventingpertussis: evidence of rapidly waning immunity and differencein effectiveness by Tdap brand. J. Infect. Dis., 2014; 210: 942-953
  Google Scholar
• 42. Koj S., Niedziela T., Ługowski C.: Bordetella pertussis LOS-derivedoligosaccharide with pertussis toxin glycoconjugate and its applicationin the prophylaxis and treatment of infections caused byBordetella pertussis. Patent WO/2014/195881. 11.12.2014
  Google Scholar
• 43. Kubler-Kielb J.: Conjugation of LPS-derived oligosaccharidesto proteins using oxime chemistry. Methods Mol. Biol., 2011; 751:317-327
  Google Scholar
• 44. Kubler-Kielb J., Pozsgay V.: A new method for conjugation ofcarbohydrates to proteins using an aminooxy-thiol heterobifunctionallinker. J. Org. Chem., 2005; 70: 6987-6990
  Google Scholar
• 45. Kubler-Kielb J., Vinogradov E., Ben-Menachem G., Pozsgay V.,Robbins J.B., Schneerson R.: Saccharide/protein conjugate vaccinesfor Bordetella species: preparation of saccharide, development of newconjugation procedures, and physico-chemical and immunologicalcharacterization of the conjugates. Vaccine, 2008; 26: 3587-3593
  Google Scholar
• 46. Kubler-Kielb J., Vinogradov E., Lagergård T., Ginzberg A., KingJ.D., Preston A., Maskell D.J., Pozsgay V., Keith J.M., Robbins J.B.,Schneerson R.: Oligosaccharide conjugates of Bordetella pertussis andbronchiseptica induce bactericidal antibodies, an addition to pertussisvaccine. Proc. Natl. Acad. Sci. USA, 2011; 108: 4087-4092
  Google Scholar
• 47. Le Blay K., Caroff M., Blanchard F., Perry M.B., Chaby R.: Epitopesof Bordetella pertussis lipopolysaccharides as potential markersfor typing of isolates with monoclonal antibodies. Microbiology,1996; 142: 971-978
  Google Scholar
• 48. Le Dur A., Caroff M., Chaby R., Szabó L.: A novel type of endotoxinstructure present in Bordetella pertussis. Isolation of two differentpolysaccharides bound to lipid A. Eur. J. Biochem., 1978; 84: 579-589
  Google Scholar
• 49. Ługowski C., Niedziela T., Jachymek W.: Endotoksyny bakteryjne:struktura, aktywności biologiczne, szczepionki koniugatowe.Mikrobiol. Med., 1996; 4: 28-39
  Google Scholar
• 50. Mahon B.P., Ryan M.S., Griffin F., Mills K.H.: Interleukin-12 isproduced by macrophages in response to live or killed Bordetella pertussisand enhances the efficacy of an acellular pertussis vaccine bypromoting induction of Th1 cells. Infect. Immun., 1996; 64: 5295-5301
  Google Scholar
• 51. Marr N., Novikov A., Hajjar A.M., Caroff M., Fernandez R.C.:Variability in the lipooligosaccharide structure and endotoxicityamong Bordetella pertussis strains. J. Infect. Dis., 2010; 202: 1897-1906
  Google Scholar
• 52. Marzouqi I., Richmond P., Fry S., Wetherall J., Mukkur T.: Developmentof improved vaccines against whooping cough: currentstatus. Hum. Vaccin., 2010; 6: 543-553
  Google Scholar
• 53. Mattoo S., Cherry J.D.: Molecular pathogenesis, epidemiology,and clinical manifestations of respiratory infections due to Bordetellapertussis and other Bordetella subspecies. Clin. Microbiol. Rev.,2005; 18: 326-382
  Google Scholar
• 54. Mills K.H., Ross P.J., Allen A.C., Wilk M.M.: Do we need a newvaccine to control the re-emergence of pertussis? Trends Microbiol.,2014; 22: 49-52
  Google Scholar
• 55. Mooi F.R., Van Der Maas N. A., De Melker H.E.: Pertussis resurgence:waning immunity and pathogen adaptation – two sides of thesame coin. Epidemiol. Infect., 2014; 142: 685-694
  Google Scholar
• 56. Mooi F.R., van Loo I.H., van Gent M., He Q., Bart M.J., HeuvelmanK.J., de Greeff S.C., Diavatopoulos D., Teunis P., Nagelkerke N.,Mertsola J.: Bordetella pertussis strains with increased toxin productionassociated with pertussis resurgence. Emerg. Infect. Dis., 2009;15: 1206-1213
  Google Scholar
• 57. Mountzouros K.T., Kimura A., Cowell J.L.: A bactericidal monoclonalantibody specific for the lipooligosaccharide of Bordetella pertussis reduces colonization of the respiratory tract of mice afteraerosol infection with B. pertussis. Infect. Immun., 1992; 60: 5316-5318
  Google Scholar
• 58. Niedziela T., Letowska I., Lukasiewicz J., Kaszowska M., CzarneckaA., Kenne L., Lugowski C.: Epitope of the vaccine-type Bordetellapertussis strain 186 lipooligosaccharide and antiendotoxin activityof antibodies directed against the terminal pentasaccharide-tetanustoxoid conjugate. Infect. Immun., 2005; 73: 7381-7389
  Google Scholar
• 59. Paradowska-Stankiewicz I., Rudowska J.: Pertussis in Poland in 2010 Przegl. Epidemiol., 2012; 66: 211-214
  Google Scholar
• 60. Parkhill J., Sebaihia M., Preston A., Murphy L.D., Thomson N.,Harris D.E., Holden M.T., Churcher C.M., Bentley S.D., Mungall K.L.,Cerdeño-Tárraga A.M., Temple L., James K., Harris B., Quail M.A.i wsp.: Comparative analysis of the genome sequences of Bordetellapertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat.Genet., 2003; 35: 32-40
  Google Scholar
• 61. Pichichero M.E., Rennels M.B., Edwards K.M., Blatter M.M., MarshallG.S., Bologa M., Wang E., Mills E.: Combined tetanus, diphtheria,and 5-component pertussis vaccine for use in adolescents andadults. JAMA, 2005; 293: 3003-3011
  Google Scholar
• 62. Robbins J.B., Schneerson R., Kubler-Kielb J., Keith J.M., TrollforsB., Vinogradov E., Shiloach J.: Toward a new vaccine for pertussis.Proc. Natl. Acad. Sci. USA, 2014; 111: 3213-3216
  Google Scholar
• 63. Sato H., Sato Y.: Experience with diphtheria toxoid-tetanus toxoid-acellularpertussis vaccine in Japan. Clin. Infect. Dis., 1999; 28(Suppl. 2): S124-S130
  Google Scholar
• 64. Sato Y., Sato H.: Development of acellular pertussis vaccines.Biologicals, 1999; 27: 61-69
  Google Scholar
• 65. Schmidtke A.J., Boney K.O., Martin S.W., Skoff T.H., Tondella M.L.,Tatti K.M.: Population diversity among Bordetella pertussis isolates,United States, 1935-2009. Emerg. Infect. Dis., 2012; 18: 1248-1255
  Google Scholar
• 66. Schneerson R., Levi L., Robbins J.B.: Pertussis toxin used as a carrierprotein with non-charged saccharides in conjugate vaccines.Patent US 5445817 A. 1995
  Google Scholar
• 67. Sheu G.C., Wo Y.Y., Yao S.M., Chou F.Y., Hsu T.C., Ju C.L., Cheng Y.,Chang S.N., Lu C.H.: Characteristics and potency of an acellular pertussisvaccine composed of pertussis toxin, filamentous hemagglutinin,and pertactin. J. Microbiol. Immunol. Infect., 2001; 34: 243-251
  Google Scholar
• 68. Skerry C.M., Mahon B.P.: A live, attenuated Bordetella pertussisvaccine provides long-term protection against virulent challenge ina murine model. Clin. Vaccine Immunol., 2011; 18: 187-193
  Google Scholar
• 69. Smith A.M., Guzmán C.A., Walker M.J.: The virulence factors ofBordetella pertussis: a matter of control. FEMS Microbiol. Rev., 2001;25: 309-333
  Google Scholar
• 70. Tan Y., Fleck R.A., Asokanathan C., Yuen C.T., Xing D., Zhang S.,Wang J.: Confocal microscopy study of pertussis toxin and toxoidson CHO-cells. Hum. Vaccin. Immunother., 2013; 9: 332-338
  Google Scholar
• 71. Tondella M.L., Carlone G.M., Messonnier N., Quinn C.P., MeadeB.D., Burns D.L., Cherry J.D., Guiso N., Hewlett E.L., Edwards K.M.,Xing D., Giammanco A., Wirsing von König C.H., Han L., Hueston L.i wsp.: International Bordetella pertussis assay standardization andharmonization meeting report. Centers for Disease Control andPrevention, Atlanta, Georgia, United States, 19-20 July 2007. Vaccine,2009; 27: 803-814
  Google Scholar
• 72. Trollfors B., Lagergard T., Taranger J., Bergfors E., Schneerson,Robbins J.B.: Serum immunoglobulin G antibody responses to Bordetellapertussis lipooligosaccharide and B. parapertussis lipopolysaccharidein children with pertussis and parapertussis. Clin. Diagn.Lab. Immunol., 2001; 8: 1015-1017
  Google Scholar
• 73. Trollfors B., Taranger J., Lagergård T., Lind L., Sundh V., ZackrissonG., Lowe C.U., Blackwelder W., Robbins J.B.: A placebo-controlledtrial of a pertussis-toxoid vaccine. N. Engl. J. Med., 1995;333: 1045-1050
  Google Scholar
• 74. Van den Berg B.M., David S., Beekhuizen H., Mooi F.R., van FurthR.: Protection and humoral immune responses against Bordetella pertussisinfection in mice immunized with acellular or cellular pertussisimmunogens. Vaccine, 2000; 19: 1118-1128
  Google Scholar
• 75. Van den Brink G., Wishaupt J.O., Douma J.C., Hartwig N.G., VersteeghF.G.: Bordetella pertussis: an underreported pathogen in pediatric respiratoryinfections, a prospective cohort study. BMC Infect. Dis., 2014; 14: 526
  Google Scholar
• 76. Weiss A.A., Mobberley P.S., Fernandez R.C., Mink C.M.: Characterizationof human bactericidal antibodies to Bordetella pertussis.Infect. Immun., 1999; 67: 1424-1431
  Google Scholar
• 77. Weiss A.A., Patton A.K., Millen S.H., Chang S.J., Ward J.I., BernsteinD.I.: Acellular pertussis vaccines and complement killing ofBordetella pertussis. Infect. Immun., 2004; 72: 7346-7351
  Google Scholar
• 78. WHO: Pertussis vaccines: WHO position paper. Wkly Epidemiol.Rec., 2010; 85: 385-400
  Google Scholar
• 79. Winter K., Harriman K., Zipprich J., Schechter R., Talarico J.,Watt J., Chavez G.: California pertussis epidemic, 2010. J. Pediatr.,2012; 161: 1091-1096
  Google Scholar
• 80. Wong K.H., Skelton S.K.: New, practical approach to detectingantibody to pertussis toxin for public health and clinical laboratories.J. Clin. Microbiol., 1988; 26: 1316-1320
  Google Scholar
• 81. Wood N., McIntyre P.: Pertussis: review of epidemiology, diagnosis,management and prevention. Paediat. Respir. Rev., 2008;9: 201-211
  Google Scholar
• 82. Woodward M.P., Young W.W.Jr., Bloodgood R.A.: Detection ofmonoclonal antibodies specific for carbohydrate epitopes usingperiodate oxidation. J. Immunol. Methods, 1985; 78: 143-153
  Google Scholar
• 83. Zieliński A., Borys D.: Problem nawrotu zachorowań na krztusiec.Przegl. Pediatr., 2002; 32: 273-277
  Google Scholar
• 84. Zieliński A., Czarkowski M.P., Sadkowska-Todys M.: Infectiousdiseases in Poland in 2012. Przegl. Epidemiol., 2014; 68: 177-185
  Google Scholar

Full text